IL-10 as a Predictor in Renal Cell Carcinoma
Author Information
Author(s): Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, Wandert T, Ganser A, Atzpodien J
Primary Institution: Medizinische Hochschule Hannover
Hypothesis
Can pretreatment serum levels of IL-10 predict outcomes in patients with metastatic renal cell carcinoma?
Conclusion
Elevated levels of IL-10 in patients are linked to worse outcomes in metastatic renal cell carcinoma.
Supporting Evidence
- IL-10 has been detected in tumor cell cultures of renal cell carcinoma.
- IL-10 can suppress antigen-presenting cells and may lead to down-regulation of HLA class I and II molecules.
- An elevated pretreatment serum level of IL-10 was a statistically independent predictor of unfavorable outcome.
Takeaway
Doctors found that higher levels of a substance called IL-10 in the blood can mean that patients with kidney cancer might not do as well.
Methodology
The study evaluated serum levels of IL-10 and clinical parameters using univariate and multivariate Cox proportional hazards models.
Participant Demographics
Patients with advanced renal cell carcinoma seen between May 1990 and April 1996.
Statistical Information
P-Value
0.0028
Statistical Significance
p<0.0028
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website